Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$1.26
+0.8%
$0.99
$0.53
$1.90
$98.23M1.06397,906 shs138,565 shs
InspireMD, Inc. stock logo
NSPR
InspireMD
$2.47
+2.9%
$2.42
$1.99
$3.80
$100.13M0.6104,300 shs549,290 shs
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
$3.00
+15.4%
$2.89
$2.37
$7.04
$100.47M0.62452,213 shs944,027 shs
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$4.69
+1.3%
$4.62
$1.98
$7.95
$34.71M7.03187,155 shs244,831 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-3.47%-3.10%+15.74%+89.39%+20.19%
InspireMD, Inc. stock logo
NSPR
InspireMD
+0.84%-3.61%-1.23%-3.61%-18.09%
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
+1.96%-1.14%-20.97%-7.80%-60.73%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
+10.24%+4.04%-11.64%+103.96%+71.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hyperfine, Inc. stock logo
HYPR
Hyperfine
1.7165 of 5 stars
1.35.00.00.03.51.70.6
InspireMD, Inc. stock logo
NSPR
InspireMD
3.4009 of 5 stars
3.55.00.00.00.64.20.6
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
3.315 of 5 stars
3.55.00.00.03.12.50.0
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
0.81 of 5 stars
1.34.00.00.02.30.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hyperfine, Inc. stock logo
HYPR
Hyperfine
2.67
Moderate Buy$1.281.85% Upside
InspireMD, Inc. stock logo
NSPR
InspireMD
3.00
Buy$4.5082.19% Upside
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
3.00
Buy$14.00366.67% Upside
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
2.50
Moderate Buy$4.822.70% Upside

Current Analyst Ratings Breakdown

Latest VVOS, NSPR, HYPR, and OBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
8/15/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$0.68 ➝ $0.85
8/14/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $2.00
8/13/2025
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/7/2025
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/3/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$12.89M7.68N/AN/A$0.45 per share2.80
InspireMD, Inc. stock logo
NSPR
InspireMD
$7.07M14.58N/AN/A$1.83 per share1.35
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
$2.64M43.91N/AN/A$0.01 per share300.00
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$15.03M2.34N/AN/A$0.61 per share7.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$40.72M-$0.52N/AN/AN/A-364.54%-84.82%-69.39%11/11/2025 (Estimated)
InspireMD, Inc. stock logo
NSPR
InspireMD
-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/A
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
-$61.02M-$1.83N/AN/AN/A-2,367.49%-289.42%-110.04%11/11/2025 (Estimated)
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$11.14M-$1.68N/AN/AN/A-99.49%-232.76%-84.30%11/13/2025 (Estimated)

Latest VVOS, NSPR, HYPR, and OBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2025Q2 2025
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$0.39-$0.55-$0.16-$0.55$3.37 million$3.82 million
8/13/2025Q2 2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$0.12-$0.12N/A-$0.12$3.00 million$2.70 million
8/12/2025Q2 2025
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
-$0.51-$0.50+$0.01-$0.50$0.78 million$0.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hyperfine, Inc. stock logo
HYPR
Hyperfine
N/AN/AN/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
N/AN/AN/AN/AN/A
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
N/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hyperfine, Inc. stock logo
HYPR
Hyperfine
N/A
5.02
4.41
InspireMD, Inc. stock logo
NSPR
InspireMD
N/A
6.39
6.05
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
48.76
2.10
2.09
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
1.69
1.05
1.05

Institutional Ownership

CompanyInstitutional Ownership
Hyperfine, Inc. stock logo
HYPR
Hyperfine
15.03%
InspireMD, Inc. stock logo
NSPR
InspireMD
44.78%
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
53.20%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26.35%

Insider Ownership

CompanyInsider Ownership
Hyperfine, Inc. stock logo
HYPR
Hyperfine
30.98%
InspireMD, Inc. stock logo
NSPR
InspireMD
34.06%
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
8.10%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hyperfine, Inc. stock logo
HYPR
Hyperfine
19078.58 million54.24 millionOptionable
InspireMD, Inc. stock logo
NSPR
InspireMD
5041.72 million18.33 millionOptionable
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
438.64 million35.51 millionNot Optionable
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
1607.50 million7.28 millionOptionable

Recent News About These Companies

Vivos Reports 7% Sales Drop

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hyperfine stock logo

Hyperfine NASDAQ:HYPR

$1.26 +0.01 (+0.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.28 +0.02 (+1.98%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

InspireMD stock logo

InspireMD NYSE:NSPR

$2.47 +0.07 (+2.92%)
Closing price 04:00 PM Eastern
Extended Trading
$2.48 +0.01 (+0.40%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Orchestra BioMed stock logo

Orchestra BioMed NASDAQ:OBIO

$3.00 +0.40 (+15.38%)
Closing price 04:00 PM Eastern
Extended Trading
$3.00 +0.00 (+0.17%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Vivos Therapeutics stock logo

Vivos Therapeutics NASDAQ:VVOS

$4.69 +0.06 (+1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$4.84 +0.15 (+3.30%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.